Tegoprubart (AT-1501)

May 20, 2026 — Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) announced it will present new clinical data on tegoprubart (an investigational anti-CD40L antibody) in kidney transplantation at the American Transplant Congress (ATC) in Boston, June 20–24, 2026. The company will deliver an oral presentation featuring updated results from the Phase 2 BESTOW trial and a poster presenting new long-term findings from the Phase 2 BESTOW extension study, both evaluating tegoprubart’s safety and efficacy for prevention of kidney transplant rejection. The oral abstract (Publication No. 585) will be presented June 22, 2026 (12:03–12:15 p.m. ET) by Andrew Adams, M.D., Ph.D. (University of Minnesota / M Health Fairview). Eledon will also host a conference call/webcast on June 22, 2026 at 8:00 a.m. ET to discuss the updated and long-term data. Business significance: the announcements signal ongoing clinical progress and upcoming data readouts supporting tegoprubart’s potential as a non-lymphocyte-depleting immunomodulatory option in transplant rejection prevention.